Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance

• Published in: Blood 2022-11, Vol.140 (18), p.1997-2000
• Main Authors: Ho, Matthew, Zanwar, Saurabh, Buadi, Francis K., Ailawadhi, Sikander, Larsen, Jeremy, Bergsagel, Leif, Binder, Moritz, Chanan-Khan, Asher, Dingli, David, Dispenzieri, Angela, Fonseca, Rafael, Gertz, Morie A., Gonsalves, Wilson, Go, Ronald S., Hayman, Suzanne, Kapoor, Prashant, Kourelis, Taxiarchis, Lacy, Martha Q., Leung, Nelson, Lin, Yi, Muchtar, Eli, Roy, Vivek, Sher, Taimur, Warsame, Rahma, Fonder, Amie, Hobbs, Miriam, Hwa, Yi L., Kyle, Robert A., Rajkumar, S. Vincent, Kumar, Shaji
• Format: Article
• Language: English
• Subjects: COVID-19; Humans; Letter to Blood; Monoclonal Gammopathy of Undetermined Significance - complications; Monoclonal Gammopathy of Undetermined Significance - epidemiology; Multiple Myeloma - complications; Paraproteinemias - complications; Risk Factors
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.2022017616

Two Letters to Blood address the risks of COVID-19 in populations with precursors of hematological disease. In the first article, Miller and colleagues report on whether clonal hematopoiesis of intermediate potential (CHIP) is associated with adverse outcomes with COVID-19, finding no association between CHIP and 28-day mortality while providing data indirectly linking IL-6 signaling and patient outcomes. In the second article, Ho and colleagues investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS) with COVID-19, reporting that one-fourth had a severe infection and that on multivariable analysis, adverse outcomes are more likely if immunoparesis is present.